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Abstract
Chitosan (CS) is a polycation with a pka of about 6.3 with a charge density dependent on pH and the %DA-value which can interact with 
polyanions to form complex and gels. Nanoparticles (CNPs) in addition can increase the antifungal potential of bioactive compounds 
like essential oils by increasing cellular interactions between them and the fungal as a result of the very small size that enhances cellular 
uptake. In this study, was set to investigate the encapsulation of the Gymnema sylvestre essential oils (G.EOs) using Chitosan and Myrestic 
acid made Nanogel in order to enhance its antifungal activity and stability to the oil against C. albicans strain (ATCC 10231). To procedure 
this, the self-assembled process of Chitosan and Myrestic acid Nanogel (CS-MA) through the 1- ethyl - 3- (3 dimethyl aminoprophyl) 
carbodiimide (EDC) was designed. Its physicochemical properties were determined by Fourier Transforms Infrared spectroscopy (FT-
IR), X-ray diffraction (XRD), and microscopic methods by Atomic force microscopy (AFM), Transmission Electron Microscopy (TEM), and 
Scanning Electron Microscopy (SEM). Minimum inhibitory concentration (MIC) at 18.7 to 37.5 µg/ml and 2.3 to 4.6 µg/ml and minimal 
fungicidal concentration (MFC) at 75 µg/ml and 5.38 µg/ml using by broth micro dilution (BMD) method for G. sylvestre oils (G.EOs) 
and oil-loaded Nanogels (G.OLNPs) were measurement. The susceptibility of C. albicans biofilm to fractions was examined by 2,3-bis 
(2-methoxy-4-nitro-5-sulfophenyl)-5-[8phenylamino) carbonyl] - 2H - tetrazolium hydroxide (XTT) quantitatively.
The concentration of G.OLNPs required to inhibit 50  % biofilm formation was 4.68 µg/ml, while that to remove 90  % biofilm 
growth was 18.07 µg/ml. In addition, it was observed that cell uptake of G.OLNPs was much higher compared with free G.EOs. 
Reverse transcription polymerase chain reaction (RT-PCR) analysis was performed to determine the effect of sub-MIC concentrations 
of G.EOs and G.OLNPs on expression of the biofilm–related gene ALS1 / ALS3, and indicated the G.OLNPs down-regulated the 
expression of hypha-specific gene ALS3. Furthermore, the data strongly suggested that G.OLNPs more effective suppressed 
C. albicans planktonic cells and reduction biofilm biomass.
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1 Introduction
Candida species are the prevalent human fungal pathogen 
that poses the significant medical challenge [1]. In recent 
decades systemic infection caused by the C. albicans in 
immunosuppressed patients such as transplant recipients 
and cancer patients undergoing cytotoxic chemotherapy, 
Diabetes, a variety of hematologic malignancy and HIV, 
have been increased [2]. Most manifestations of candidia-
sis are associated with biofilm formation (BF) occurring on 
the surface of host tissue and medical devices, which plays 
an essential role in the pathogenicity of C. albicans [3, 4]. 
Biofilm is a complex network of microorganism's accumu-
lation in a matrix Exo-polymer hydrophobic which can be 
attached to various biotic and abiotic surfaces [5, 6].
The transition from the yeast to the hyphal form allows the 
pathogen not only to invade tissue and causes oxidative stress 
resistance but also to escape from immune surveillance, it 
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can facilitate the adhesion of other microorganisms is con-
ducive to fungal diseases [7, 8]. Lastly, degrading hydro-
lases, phenotypic switching, and adherence to host surfaces 
and the secreted aspartyl proteinase and lipase families are 
associated by a large gene family, particularly the aggluti-
nin-like sequence (ALS) [9, 10]. The ALS gene family is 
the largest family among known adhesions in C. albicans 
[10]. Each ALS gene has a similar three-domain structure, 
including a 5' domain of 1299-1308 bp that is 55 % - 90 % 
identical across family; a central domain is composed of 
a 108 bp motif repeating. This domain is responsible for 
encryption protected of 36 amino acids and a 3' domain has 
a variable length but the sequence alkaline with other mem-
bers of the gene has a similar structure [11]. The finding 
that expression of ALS1 and ALS3 increases during biofilm 
development in vitro suggested that the ALS family played 
a role in biofilm formation [12]. Recently, Bastidas et al. [13] 
found that expression of ALS3 inhibited under conditions of 
high nutrient availability.
A common issue associated with C. albicans biofilms 
is the increased resistance of these biofilms to antifun-
gal agents such as azole drugs and their derivatives and 
to host immune defences [14, 15]. Resistance mechanisms 
such as limited influence of drugs due to fungus-resistant 
matrix, switch phenotype leading to slower growth or food 
restrictions with gene expression ALS1 / ALS3 is increased 
and to lead resistance to antibiotic treatment [16, 17]. 
Therefore, it has become an urgent medical that needs to 
develop a safer and better drug delivery system increas-
ingly. Pharmaceutical sciences to reduce toxicity or side 
effects of drugs used nanoparticles (NPs).Among these 
polymeric NPs, chitosan (CS)-based nanocarriers (CSNPs) 
have received much attention as a drug-delivery system.
Chitosan is a liner polysaccharide composed of ran-
domly distributed ß-(1→4)-link D-glucosamine (deacetyl-
ated unit) and N-acetyl-D-glucosamine (acetylated 
unit) [18]. The NH
2
- and OH- groups endow chitosan with 
many special properties, making it applicable to many 
areas and easily available for chemical reactions [19]. 
After structural manipulation and functionalization of CS, 
drug molecules can be encapsulated and the advantages of 
it allow for a greater control of the active drug pharmaco-
kinetic behaviour [20].
These methods, in principle, can be divided into, cross-
linked networks of the polymer chain formed via covalent 
linkage or self-assembly process. The present study was 
set to produce Nanogel through the formation amid link-
ages between amino group of chitosan, to the carboxyl 
group in myristic acid (MA; C
14
H
28
O
2
) by self-assembly 
technique [21]. The reaction to the formation of hydro-
gen nanoparticles that can be encapsulated or controlled 
release of the drug used [3].
In their investigation, Rabea et al. [22] and Sudarshan 
et al. [23] reported that nano chitosan cuts down the met-
abolic activity and durability of Candida species biofilms. 
This phenomenon may be caused by a tension in the bio-
film structure that increases the permeability of cell mem-
branes, penetration of nano chitosan, and fungus removal. 
Shrestha et al. [24] showed that fungal biofilm was signifi-
cantly reduced after exposure to nano chitosan particles.
In addition, due to their nano scaled dimension 
Nanogels are responsive to the effects of environmental 
factors such as light, ionic strength, pH, and temperature 
on bioactive compounds such as essential oils (EOs). The 
plant mediated synthesis is a rapid, flexible and suitable 
process for large scale production of nanoparticle. 
Gymnema sylvestre is one of the most important 
medical plants in India and belongs to the family of 
Asclepiadaceae [25]. G. sylvestre is otherwise popularly 
known as gurmar and Madhunashini. Essential oils this 
plant consisted of flavonoids, and alkaloids are major 
groups of phenolic compounds [26]. Gymnemic acids 
(GAs) are reported to be the main class of chemical con-
stituents of G. sylvestre is known for its significant antidi-
abetic, antifungal and antibacterial properties against var-
ious pathogenic population activities (Scheme 1).
The objective of this research was to evaluate the effect 
of the fabrication of CSNPs based on, antifungal activity. 
G. sylvestre essential oils (G.EOs) and essential oils load-
ing in Nanogels (G.OLNPs) have on efficient impacted on 
growth of the planktonic cells and biofilm formation (BF) 
C. albicans strain ATCC 10231. In addition, RT - PCR was 
discussed on treated and untreated ALS1 / ALS3 gene exp-
ression in sessile cells of C. albicans.
Scheme 1 Basic structure of Gymnemic acids (GAs)
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2 Materials and Methods
2.1 Formation and characterization of the G.OLNPs
2.1.1 Preparation of CS-MA (Chitosan- Myristic acid) 
Nanogel
The water-soluble EDC1 is called "Zero-length" Cross-
linker because the amide linkage is formed without leav-
ing a spacer molecule [27]. CS-MA Nanogel was designed 
for preservation and controlled release of G.EOs by the 
technique of self-assembly according to a modification of 
the method of Chen et al [28].
Myristic acid solution was prepared by dissolving 
0.1 gr MA (Sigma Aldrich ≥ 99 %, Mw = 228.37 g/mol) in 
10 mL ethanol. Chitosan (1 g) (Sigma Aldrich, degree of 
deacetylation (DD): 75-85 %, medium molecular weight 
of: 250 kDa, 200-800 cP viscosity of %1 w/v) was dis-
solved in 100 mL aqueous acetic acid (1% v/v; pH = 3.35) 
solution and sonicated using a probe type sonifire (ultra-
sonic homogenizer VH-600) at 60 w for 20 min and then 
diluted with methanol. Polymer complex of myristic acid 
and chitosan covalently joined together by the forma-
tion of amide linkages through the EDC (Sigma-Aldrich, 
Mw = 155.24 g/mol, d = 0.814 g/mL) mediated reaction. 
EDC (0.1 g) and NHS2 (0.1 g) was dissolved in methanol, 
then added into the MA solution. The 1 : 1 mol ratio of 
EDC to MA was utilized in this paper.
EDC reacts with the carboxyl group of MA to form an 
active ester intermediate, which can further react with a 
primary amine of CS to form an amide bond. Afterwards, 
MA solution was added to the chitosan solution followed 
by a drop wisely, while stirring under the hood at room 
temperature for 24 h [29]. The precipitated material was 
washed with distilled water and ethanol by ultracentrifuge 
and dried under vacuum for 24 h at room temperature. 
Dried Nanogels were kept in a refrigerator at 4 °C until 
required in the analysis (Scheme 2).
2.2 Physicochemical characterization of G.OLNPs
2.2.1 Scanning Electron Microscopy (SEM) analysis
SEM is a method for high resolution imaging of surface. 
Sample was prepared on a glass slide (1 × 1 cm) after 
washing it with ethanol. A tiny drop of nano dispersion 
was spread evenly over glass slide and allowed to air dry. 
Morphology and size G.OLNPs consist of the surface and 
shape nano capsule walls were observed by using Philips: 
XL30 analytical SEM.
1 1-ethyl-3-(3-dimethylaminopropyl ) carbodiimide hydrochloride.
2 N-hydroxysuccinimide
2.2.2 3D Structure Evaluation: Atomic force 
microscopy (AFM)
While SEM provides 2 dimensional (2D) images of sam-
ple, AFM studies were performed to get the 3 dimensional 
(3D) images. AFM imaging was carried out by using scan-
ning probe microscope (Entegra Afmnt-mdt; Company: 
NT-MDT) in tap model. Samples were prepared in a fashion 
as for SEM analysis without any further sample treatment.
2.2.3 Transmission Electron Microscopy (TEM) 
Morphological characteristics, bio reductive formation and 
existence of CS-MA Nanogel was analysed by high-resolu-
tion TEM. One drop of the sample suspensions was placed 
on carbon-coated TEM grids. After one minute, the grids 
were dried using filter paper and the nanostructure was con-
ducted with a Philips EM208S Transmission electron micro-
scope (Germany) at acceleration voltage of 100 kV [30].
2.2.4 Release kinetics of G.OLNPs analysis
To determine release pattern G.OLNPs was assessed by 
spectrophotometer. The amount of 1 mg of the formula-
tion was transferred into dialysis bags (molecular weight 
cut-off, 6-8 kDa) in 25 ml of buffer PBS (pH = 7.4) and 
sonicated (Sonic Purger CQ250) in water bath at room 
temperature for 5 min and afterwards shaken horizontally 
(Incubator Shaker HZ-88125) during a one-week period. 
Scheme 2 Myristic acid modified chitosan
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After that, the drug released in the buffer solution was 
measured at a wavelength 195 nm by spectrophotometry. 
Finally, the percentage of drug release was prepared using 
the standard curve and monitoring afterwards.
The Nanogel release profile was determined using Eq. (1):
Mt M Ktn∞ =  (1)
where Mt ⁄ M∞. It denotes the fraction of oil released ( t ) is the 
release time, and (K) represents a constant characteristic of 
the system [31]. The diffusion exponent (n) is an indication 
of the mechanism of oil release and takes values depend-
ing on the geometry of the release device. A linear form of 
Eq. (1) can be obtained by plotting ln Mt ⁄ M∞ against ln t, 
whose angular coefficient is n and the linear coefficient is k.
2.2.5 X-ray Diffraction (XRD)
The pattern of transparency of CS-MA Nanogel with a WR 
of 0.2 were recorded in powdered thin film of Nanogel at 500 
nm using X-ray diffractometer (Lamda 35, Perkin-Elmer) at 
1 step / second. The method is non-destructive and does not 
require sample preparation. The diffraction patterns was 
set up to determine the crystalline phases of the sample and 
measuring the structural properties. Data was taken for the 
at 2Ɵ range of 4 to 88 degrees with a step size of 0.001°.
2.2.6 Fourier Transformation Infrared Spectrometry 
(FTIR) analysis
In order to, interaction and bonding analysis of EOs with 
CSNPs Nanogel FTIR studies were conducted to get infor-
mation about an effective drug delivery system. It is nec-
essary that the active agent must be released slowly from 
the carrier moiety. Spectrums of Infrared Radiation (IR) 
were recorded by the 460-type spectrometer (Shimudza 
Co. Japan) under dry air at room temperature, following 
the method described [32]. For the IR spectroscopic analy-
sis, 2 mg of MA, 2 mg of CS and 100 µl of CS-MA Nanogel 
was separately mixed with 100 mg of KBr and made into 
pellets at 20 °C. The instrument was operated with fre-
quency range of 500-4000 cm-1. The resulted peaks in the 
FTIR spectrum were used to derive a dose-response curve 
and provide pharmacological information [33].
2.3 Antifungal Activity
2.3.1 Preparation of standard fungal cell suspension
Candida albicans (strain 10231) was purchased from the 
American Type Culture Collection (ATCC). The fungal 
cells were grown on YPD agar [1 % (w/v) yeast extract, 
2 % (w/v) mycological pepton, 2 % dextrose, 2 % agar], at 
35 °C for 24 h with agitation and passaged at least twice 
to ensure purity and viability. Inocula was prepared by 
picking five colonies of about 1 mm in diameter from 
24-h-old cultures of Candida albicans [34]. The colo-
nies were suspended in 5 ml of phosphate-buffered saline 
(PBS; pH = 7.2). The resulting suspension was vortexed 
for 15 s, and the cell density was adjusted to an optical 
density at 520 nm. This procedure yield a yeast stock sus-
pend (1 × 103 cells/mL).
2.3.2 Antifungal effect of compounds against 
planktonic cells 
For individual susceptibility profile of planktonic cells, 
broth microdilution (BMD) assay was performed based on 
version of M27-A3 documents according to the guidelines of 
CLSI (Clinical and Laboratory Standards Institute) [35, 36]. 
Stock suspensions of the antifungal agents of G.EOs and 
Itraconazole (ITZ; Janssen Research Foundation, Beerse, 
Belgium) according to the manufacturer's instructions 
were added with sterile DMSO (dimethyl sulfoxide; Sigma 
Chemical Co., St. Louis, MO, USA) and was diluted in 
the standard RPMI 1640 medium (Sigma Chemical Co. 
Germany) buffered with morpholine propane sulfonic acid 
(MOPS pH = 7.0; 0. 165 mol L; Sigma) with L-glutamine 
without biocarbonate to yield two times their concentra-
tions [37]. Briefly, two-fold of serial doubling dilutions of 
G.EOs (2.3 µg/mL to 300 µg/mL), G.OLNPs in final con-
centration ranged (1.7 µg/mL to 150 µg/mL) and itracon-
azole were adjusted as follows (0.016 µg/mL to 64 µg/mL) 
against planktonic cells with YNB medium (YNB; 0.67 % 
yeast nitrogen base, amino acids, 2 % dextrose; Difco 
Laboratories, Detroit, MI, USA) were added in 96-well 
microtiter plates (Costar. 3599, Corning). After the addi-
tion of inocula stock suspend (1 × 103 cells/mL) prepared 
as described above, plates were incubated at 35 °C for 24 
and 48 h to determine MIC values. The Minimal Inhibitory 
Concentrations (MICs) were determined visibly with the 
aid of a reading mirror, according to NCCLS guidelines. 
SubMIC90 were defined as the lowest concentrations exhib-
iting ˂ 90 % inhibition of visible growth compared with the 
growth of a drug free control. MFC (Minimal Fungicidal 
Concentration) were defined as the lowest concentrations 
that did not allow visible growth on subculture when 10 µl of 
the well content were cultured on SDA agar for 24 h at 37 °C. 
To avoid antifungal carryover, aliquots were deposited at a 
spot on the agar plate and allowed to soak then streaking was 
performed as described by Moore et al. [38]. Each experi-
ment was repeated in duplicate.
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2.3.3 Biofilm formation and drug treatment
Fungal biofilm was studied as describe on commercially 
available, pre-sterilized, microtiter plate model with minor 
modification [38]. Briefly, aliquots of 100 µL of the stan-
dardized cell suspensions of C. albicans (1 × 103 cells / mL) 
in YNB medium containing 100 mM D-glucose were trans-
ferred into each well of 96-well polystyrene microtiter 
plates that was previously coated with BSA (Bovin Serum 
Albumin), and incubated 90 min in an orbital shaker (Stuart 
Scientific, UK75rpm) at 37 °C. After the adhesion phase, the 
liquid was aspirated and each well was washed three times 
with sterile PBS to remove loosely attached cells. For mature 
biofilm to develop, 100 mL of dilutions of antifungal agents 
in fresh YNB medium containing 100 mM D-glucose and 
fresh RPMI - MOPS in a total volume of 200 µL were added 
to biofilms for 48 h in an orbital shaker at 37 °C. For a sub-
set of assays, after 24 h of drug treatment, biofilms were 
washed with PBS. The concentrations studied were as fol-
lows: G.EOs and G.OLNPs (2.3 µg/mL to 150 µg/mL) and 
ITZ at concentrations ranging (0.04 µg/mL to 64 µg/mL) as 
standard antifungal drug, were added to each well and the 
plates incubated for 24 h at 37 °C. Each assay was performed 
in triplicate and repeated in two independent experiments.
2.3.4 Quantitative Analysis - XTT Reduction Assay
The metabolic activity of biofilms was quantified using the 
(XTT) 2,3-bis (2-methoxy-4-nitro-5-sulfophenyl)-5-[8(phe-
nylamino)carbonyl]-2H-tetrazolium hydroxide reduction 
assay established by Ramage et al. [4]. Following incubation 
the cells for the required period, a supernatant was thoroughly 
removed and plate well was washed twice with 200 ml sterile 
PBS. The fungal cell viability was quantified using a colori-
metric XTT (Sigma, St Louis, MO, USA) assay that would 
reduce XTT tetrazolium salt to XTT formazan by measuring, 
the activity of mitochondrial dehydrogenase [39].
Briefly, a saturated solution of XTT was dissolved in 
Ringer's lactate to 1 mg/mL. This XTT solution was filter 
sterilized (0.22 mm pore size filter) and stored at -70 °C. 
menadione (sigma) was dissolved in acetone to 1 mM. The 
reagent was prepared fresh prior to each assay and con-
tained 12.5 parts XTT/1 part menadione. 100 µL XTT/
menadione were added to each well with prewashed bio-
films and incubated for 3 h in dark conditions at 37 °C.
The colorimetric change during XTT assay, expressed 
as OD, was measured using a microtiter plate reader at 
A505 [40]. Higher OD values indicate an increased num-
ber of surviving candida in the biofilm. Percentage inhibi-
tion was calculated using this equation (A490 of the test ⁄ 
A490 of the non-treated control) × 100 %. The results were 
expressed MBIC50 and MBIC90 were defined as the con-
centration that showed 50 % and 90 % inhibition of bio-
film formation. All experiments were performed in tripli-
cate. YNB medium containing no inoculum (no biofilm) 
was used as control. The results were expressed as average 
± standard deviation (SD).
3 Molucular Activity
3.1 RT - PCR (Reverse transcriptase – polymerase 
chain reaction) analysis of ALS1 / ALS3 genes
RT - PCR analysis was conducted as described previ-
ously [41]. For RNA extraction and analyse the expression 
of ALS1 and ALS3 genes, a 24 h biofilm cultures grown 
with and without treatment in MICs concentration of 
G.EOs and G.OLNPs in 12-well tissue culture polystyrene 
plates was isolated. The RNA extracted was reverse tran-
scribed to cDNA and subjected to PCR using ALS1 / ALS3 
gene-specific primers (Table 1). Briefly, after re-suspend-
ing the biofilms by pipetting was washed gently with sterile 
PBS. The cells were re-suspended in 200 µL of lysis buffer 
containing (200 mM Tris-Hcl [pH = 7.5]; 10 mM EDTA 
[pH = 8.0]; 0.5 M NaCl), 200 µL of phenol-chloroform-iso-
amylalchol (25 : 24 : 1) and glass beads, were mixed, and the 
tube was strongly vibrate for 60 min. After centrifuging at 
5000 rpm for 3 min, the supernatant was transferred to a 
new tube, and 300 µl of choloroform was added. After cen-
trifuging, the aqueous phase was moved to a clean tube and 
then 1 volume of cold isopropanol was added and reserved 
at -20 °C for 15 min. On the other, the sample was washed 
twice with 70 % ethanol and with 30 µl distilled water 
kept at -20 °C. The RNA samples were treated with 1 U 
of DNase (Fermentas) per 10 µL of RNA at 37 °C for 1 h 
and then its quality checks by electrophoresis on agarose 
gel (Merck). Synthesis of cDNA was using 2-step RT-PCR 
Kit (Vi-vantis, Malaysia) according to the manufacturer's 
instruction and directly used in RT - PCR assay. The reac-
tion solution consisted of 2 µL 10X Viva Buffer A, 18.5 µL 
distilled water, 1-2 µL cDNA and 0.35 µL both forward 
and reverse primers for each gene. In continue, the micro-
tube put into thermocyler (Techne, TC-512, UK) accord-
ing to the following procedure: Initial denaturation step at 
94 °C for 5 min followed by 35 cycles consisting of dena-
turation (1 min at 94 °C), annealing(1min at 58 °C), and 
extension (1 min at 72 °C) were followed by a final exten-
sion step at 72 °C for 3 min. Finally, 25 µl of PCR prod-
uct was electrophoresed on 1.5 % agarose gel, stained with 
ethidium bromide, illuminated and documented Biorad 
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UV Transilluminator [41]. ACT1 (actin) gene was used as a 
control housekeeping gene.
3.2 Statistical analysis
Statistical analysis was performed using SPSS software 
(SPCC-Statistical Package for the Social Sciences, Inc., 
Chicago, USA) and the results were compared using a one-
way ANOVA followed Bonferroni test. The significance 
level was set at p ≤ 0.05.
4 Results 
4.1 Interaction studies of Gymnema sylvestre oil with 
CS-MA Nanogel
In the present study, CS-MA Nanogels were synthesized 
by self-assembly method. EDC was used as a cross-linker 
in order to produce CS-MA Nanogel. As mentioned 
before, the EDC–mediated attachment of the non-polar 
fatty acid (MA) to CS polymer in a polar environment 
(water), led to self–aggregation of non-polar heads inside 
ward and polar heads outside ward were detected [42].
The as-synthesized G.OLNPs, average particle size, 
global morphology and uniform share were studied using 
by SEM (Fig. 1). AFM analysis depicted CSNPs size to be 
50-100 nm with quite uniformity in both size and shape. 
The particle size of the final product was clearly observed 
to depend on planned parameters as passing the Nanogel 
through the filter, resonicasion and initial sonication during 
the synthesis procedure (Fig. 2). The designed nanoparti-
cles have average particle size of less than 100 nm were 
recorded. The observation from TEM gave us information 
about the particle shape and the determination of particle 
size and physical aggregation of nanoparticles (Fig. 3).
The release behavior of G.OLNPs in PBS buffer 
(pH = 7.4) for 7 days is described in (Fig. 4). As shown, 
all loaded essential oils were released during one week. 
On such basis, the MIC experiments were conducted 
during one week as well. At 30 °C, the cumulative release 
of G.OLNPs started at t = 24 h with 46.37 ± 2.76 % of 
total G.OLNPs was slow until t = 72 h when the release 
increased to a cumulative release of 85.04 ± 2.87 % at 
t = 120 h. At t = 168 h, 98.36 ± 2.38 % of the total quantity 
of G.OLNPs was released.
The XRD spectrum demonstrated the crystalline 
structure of the precipitant. As revealed in Figs. 5 and 6. 
Five distinct reflections are present in the diffractogram 
at 28.35° (111), 43.52° (200), 58.15° (220), 68.6° (311), 
75.34° (222). These five reflections represent the face cen-
tered cubic (fcc) structure of G.OLNPs. The strong reflec-
tion at (111), in contrast with the other four reflections may 
Table 1 ALS1, ALS3 (invasion / adhesion genes) and ACT1 
(actin reference gene) specific primers for reverse transcription- 
polymerase chain reaction assay. Forward (F) and reverse (R) 
primers used in RT-PCR
Gene Primer Sequence (5' → 3')
PCR 
product 
size 
(bp)
Accession 
number
ALS1-F
GACTAGTGAACCAACAAA
TACCAG 318 L25902
ALS1-R ACCAGAAGAAACAGCAGGTG
ALS3-F
CCAAGTGTTCCAACAACT
GAA 183 AY223552
ALS3-R GAACCGGTTGTTGCTATGGT
ACT1-F CCAGCTTTCTACGTTTCC
200 HM997110
ACT1-R CCAGCTTTCTACGTTTCC Fig. 1 Scanning electron microscopy (SEM) of the encapsulated 
G. sylvestre essential oils in Nanogel (G.OLNPs)
Fig. 2 Atomic Force Microscope (AFM) image. G.OLNPs was taken 
at room temperature
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specify the desired development track of the nano crystals. 
Unassigned peaks were also determined; indicate that the 
crystallization of bioorganic phase develops on the sur-
face of the nanoparticles [43]. Same results were described 
in G.OLNPs produced by using G.EOs.
Fourier transform infrared spectroscopy (FTIR) of CS 
shows characteristic peaks at 3433, 2920, 1647, 1088 and 
660.35 cm-1. Wide band at 3433 cm-1 (OH and NH
2
 stretch-
ing), the bands at 2920 cm-1 represent to symmetric and 
asymmetric stretching vibration of methyl groups (C-H) 
and the band at 1647 cm-1 (amide Ι) were measurement.
The symmetrical stretch of the carboxylate group can be 
assigned to the bands existing at 1426.94 cm-1. The peak at 
~ 1088 cm-1 was due to (C-O stretching). New peaks appeared 
at 1280 cm-1 (C-N stretch) in the spectrum CS-MA Nanogel 
implying the complex formation via electrostatic interaction 
between NH
3
+ groups of CS and carboxyl groups of EDC 
within the nanoparticles. All the above characteristic peaks 
also were recorded in the spectra of G.OLNPs. The major-
ity absorbance bands exiting in the spectrum of G.OLNPs 
were at 3442.20 cm-1 could stretch vibration of OH- alcohol 
groups. The strength band found at 1641 cm-1 is designated 
to attribute asymmetrical stretch of the carboxylate group. 
The symmetrical stretch of the carboxylate group can be 
assigned to the bands existing at 1280 cm-1. It proves that 
G.EOs bounce to the nanoparticles surfaces either through 
amino or carboxylate group or both (Fig. 7).
4.2 Determination of the Minimum Inhibitory 
Concentration
Table 2 summarize the in vitro susceptibility patterns 
of C. albicans ATCC 10231 , including MIC50, MIC90, 
MFC and the range of MIC values of the G. sylvestre 
essential oils (G.EOs), essential oil loaded in nanoparti-
cles (G.OLNPs) and ITZ. Our study showed that, the wid-
est range and lowest MIC for ITZ (0.016 to 64 µg/mL). 
So that, ITZ the better antifungal effect than G.OLNPs, 
but this property for G.OLNPs was greater than G.EOs 
in vitro condition. G.OLNPs, with a MIC50 of 2.3 µg/mL, 
MIC90 of 4.68 µg/mL and MFC 5.38 µg/mL, was recorded 
antifungal effect against C. albicans. On the other hand, 
G.EOs 87 % in MIC50 and MIC90 lower inhibitory 
Fig. 3 Transmission electron microscopy (TEM) of the G.OLNPs.
Fig. 4 Release kinetic of CS-MA Nanogel encapsulated G. sylvestre 
essential oils during one we
Fig. 5 X-ray diffraction (XRD) pattern of the CS-MA Nanogel.
Fig. 6 X-ray diffraction (XRD) pattern of the G.OLNPs
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activity than G.OLNPs has been shown. Although MFC 
of G.EOs is higher than MFC G.OLNPs, but it has the less 
potent in killing C. albicans planktonic cells (p < 0.05).
In concentration of 75 µg/mL, the MFC of G.EOs was 
determined about 93 % lower potential killing activity 
than G.OLNPs against isolate C. albicans. We found the 
highest MIC value for G.EOs (18.7 to 37.5 µg/mL) and the 
lowest MIC50 (0.063 to ≥ 1 µg/mL) was pertained to ITZ. 
(p ˂ 0.05).
4.3 Prevention of Biofilm Formation
Generally, the antifungal activity of G.EOs and G.OLNPs 
against C. albicans biofilms was evaluated quantitatively 
using the XTT reduction assay. The effect was concen-
tration dependent, as reflected by a progressive reduction 
in cell viability, represent by metabolic activity.
G.EOs, G.OLNPs and ITZ to be inhibited of 50 % 
sessile cells (MBIC50) in concentration 23.52 µg/mL, 
4.68 µg/mL and ≥ 16.1 µg/ml respectively and 90 % 
inhibition of sessile cells (MBIC90) in concentration 
60.97 µg/mL, 18.01 µg/mL and ≥ 24 µg/mL respectively 
was recorded (p < 0.05).
The metabolic activity of the G.OLNPs during bio-
film formation 77 % at 9.37 µg/mL, 46 % at 4.68 µg/mL 
and 39 % at 2.34 µg/mL was recorded. Therefore, in this 
inhibitory percentage (MBIC50) G.OLNPs 80 % is more 
effective of G.EOs, On other hand, in (MBIC90) the inhib-
itory percentage of G.OLNPs 71 % has been observed 
effectively (Fig. 8).
Table 2 Antifungal susceptibility test results for planktonic cells 
C. albicans ATCC 10231.
Antifungal 
agent
MIC 
range
(µg/ml)
MIC
MIC50
µg/ml
MIC90
µg/ml
Mean ± 
SD
MFC
µg/ml 
G.EOs 2.3-300 18.7 37.5 28.1 ± 9.4 75
G.OLNPs 1.17-150 2.3 4.68 3.49 ± 1.19 5.38
ITZ
0.016-
64
0.063-0.5 ≥ 1 0.53 ± 0.46 ≥ 4
(a)
Fig. 7 FT-IR spectra of (a) CS; (b) CS-MA; (c) MA Nanogel; (d) G.OLNPs
(b)
(d)(c)
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It was shown that nano chitosan essential oil can con-
siderably inhibit the growth of biofilm formation in com-
pared with ITZ.
4.4 Treatment of C. albicans strain with varying 
concentration of G.EOs / G.OLNPs for gene 
expression analysis
The results showed that Actin housekeeping gene was 
expressed at every concentration of the G.EOs and 
G.OLNPs. The Figs. 9 and 10 exhibit the representative 
gel electrophoresis results of the RT - PCR. Slight incon-
sistent level of Actin expression between different sam-
ples is because of different starting amount of RNA used 
and also the inefficiency of cDNA synthesis. However, 
this was compensated by the normalization in our cal-
culations. C. albicans treated with G.OLNPs in different 
concentration based on dose (MIC value) and higher than 
of MIC shows a general of reduction in ALS3 expression, 
compared with (MIC value) cells that treated with G.EOs. 
The ALS3 mRNA was down-regulated in concentration 
4.6 µg/mL, separately at G.OLNPs and 23.5 µg/ml in 
G.EOs (Fig. 10).
In contrast of the G.EOs and G.OLNPs there are not 
apparently significant effects on ALS1 mRNA expression 
level, as the ALS1 / actin ratio remained fairly constant for 
the conditions tested (Fig. 9). Based on analyses, reduction 
in the expression of ALS3 gene examined for this study 
was significant for G.OLNPs. A meaningful relationship 
was found between the ALS3 gene and biofilm formation 
in C. albicans isolate in XTT assay.
5 Discussion
The use of nanotechnology in medicine and more specif-
ically drug delivery is set to spread rapidly. For decades, 
pharmaceutical sciences have been using nanoparticles 
to reduce toxicity and side effects of drugs. Important 
strategies are combination therapy; application of drug 
Fig. 8 The metabolic activity of the biofilms was assessed 
quantitatively using XTT reduction assay. Results shown were 
the average of three independent experiments ± SD.  
P < 0.05 when compared with the untreated control. Fig. 9 PCR products showing presence of the ALS1 gene of Candida 
albicans. Line 1: control act1, line 2-3: gene expression of ALS1 
in isolate albicans (318 bp) treated with G.EOs; line 4-5: gene 
expression ALS1 in isolate treated with G.OLNPs. M: Marker 
molecular weight (100 bp).
ACT1 23.5↑ 18.7↑ 4.6↑ 2.3↑
Fig. 10 PCR products showing presence of ALS3 gene of Candida 
albicans. Line 1: control act1; line 2: down-regulated of the gene 
expression of ALS3 in isolate Candida albicans ATCC10231 (183bp) 
treated with G.EOs in concentration 23.5 µg/ml and line 3: gene 
expression of ALS3 with G.EOs in concentration 18.7 µg/ml; 
line 4: down-regulated of the gene expression ALS3 in isolate treated 
with G.OLNPs in concentration 4.6 µg/ml; line 5: gene expression of 
ALS3 with G.OLNPs in concentration 2.3 µg/ml.
ACT1 23.5↑ 18.7↑ 4.6↑ 2.3↑
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encapsulation in colloidal delivery systems is an effi-
cient approach to improve the pharmacokinetics of 
hydrophilic drugs and employing nanotechnology [44]. 
The recourse to naturally occurring products with inter-
esting antifungal, antimicrobial and properties such as 
chitin and chitosan and their derivatives has been getting 
more attention in the recent years. It was understood that 
nanoparticles (NPs) have particular advantages because 
they not only protect the associated drugs but also facili-
tate the drugs to go across critical and specific biological 
barriers. Targets various methods have been developed to 
fabricate chitosan nano particulate systems. Micro parti-
cles and nano chitosan particles are used in tissue engi-
neering, drug delivery and transfer of DNA vaccine [45].
Having considered the above mentioned features of CS 
and MA, Chitosan has been well reported to be the most 
widespread biopolymer having nontoxic, biocompatible 
and biodegradable characteristics [46, 47]. Additionally, 
chitosan nanoparticles have been proposed as nonviral 
vectors in gene therapy and shown adjuvant effect in vac-
cines. Absorption and bioavailability of drug encapsu-
lated into chitosan nanoparticles can be improved, so they 
can be used to deliver gene drugs, protein drugs, plant 
drugs and other compounds and can protect them effec-
tively from enzyme degradation in vivo. These extremely 
robust defence mechanisms of biofilms are lead to investi-
gate approaches to treat biofilm infections. In the drug-de-
livery field, chitosan can be used as the form of nanopar-
ticles, micro particles, hydrogels, tablets, films, and fibres 
and can interact with polyanions to from complexes 
and gels. Recent reports indicate that chitosan exhibits 
a dose-dependent blood compatibility and cell viability. 
Exhibited that nano-chitosan particles reduce biofilm for-
mation [48], which in agreement with our findings, and 
that the more the concentration of these particles, the less 
biofilm formation, and thus, there is an inverse relation-
ship between the used nanoparticle concentrations and 
biofilm formation.
On the other hand, connection of CS's NH
4
 groups to 
abutting groups such as fatty acids could create deriva-
tives, which bend to dual bonds, and this in turn enables 
them to form nano micelles in water and to encapsulate 
fats and oils, e.g. Herbal essential oils. The increased resis-
tance of candida azole drugs and the few drugs available 
for candida's treatment has led to search for new thera-
peutic alternative [49, 50]. EOs is natural plant products 
comprised of complex mixtures of biologically active sub-
stances and offer potential novel template molecules and 
bioactive compounds [51]. One of the alternatives is herbal 
plants essential oils. A set of fractions derived from the 
plant G. sylvestre consistently showed strong repressive 
activity against C. albicans yeast to hypha conversation.
Vediyappan et al. [52] reported GAs had inhibitory 
activity of C. albicans yeast to hypha conversion and ses-
sile cell's biofilm formation (BF) under several hyphae, 
including conditions such as liquid or solid RPMI and 
YPD medium containing 10 % fetal bovine serum at 37 °C. 
Moreover, the results revealed that GAs impaired hyphal 
growth in the presents of db cAMP. To further examine 
the hyphal growth inhibitory activity of GAs, germination 
and hyphal growth of the filamentous pathogenic fungus 
Aspergillus fumigatus was tested with (40 µg/mL) [52]. 
These correlate well with this study, which shows that con-
centrations of G.OLNPs could suppress hyphae formation 
several researchers have investigated the antifungal mode 
by action essential oils on gene expression C. albicans.
ALS1 and ALS3, which belong to the ALS (aggluti-
nin-Like sequence) gene family, encode cell surface gly-
coproteins [53]. ALS gene diversity genetically is caused 
protein profile of ALS has different cell-surface as a mul-
tifunctional adhesive molecule which mediates adher-
ence to diver's host substrates, such as endothelial cells, 
oral epithelial cells, gelatine, fibrinogen and laminin and 
extracellular matrix proteins [54]. It also plays an import-
ant role in biofilm formation on prosthetic solid sur-
faces [55]. In the mature while the ALS1 gene is expressed 
in the earlier stages of biofilm formation [56], the ALS3 
gene is mainly up-regulated biofilm [57]. Therefore, ALS3 
is a hypha-specific gene that is expressed by C. albicans 
hyphae and pseudo hyphae but not yeast phase organisms. 
ALS3 is a receptor for ferritin and mediates iron acquisi-
tion from the host. Therefore, C. albicans can utilize fer-
ritin as the source of iron [58]. As expected from the mul-
tifunctional nature of ALS3, mutant strain of C. albicans 
that lack this protein have prominent defects in assays of 
host cell interaction, biofilm formation, and iron acquisi-
tion in vitro [59]. The fact that ALS3 is highly expressed on 
the C.albicans surface in vivo makes it a good target for a 
vaccine. Ibrahim and Spellberg [60] found that vaccination 
with rALS3-N protects immune competent mice from both 
vaginal candidiasis and lethal disseminated candidiasis.
Finally, understanding changes in gene expression that 
are associated with biofilm formation increases the utility of 
these models for testing of potential inhibitors, and import-
ant new information about how C. albicans adherents to host, 
forms biofilms, and invades host cells. This information also 
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holds promise to lead to the development of new approaches 
to prevent and treat candida infections.
6 Conclusions
Taken together, our data demonstrate that G.EOs such as 
G.OLNPs and ITZ are active on both planktonic and bio-
film cells of C. albicans. G.OLNPs was the most effec-
tive compound tested by being active against C. albicans 
biofilms, making this compound particularly interest-
ing. Although G.OLNPs was less effective than ITZ on 
planktonic cells in our model, it is considered a less toxic 
compound than ITZ by workers in this field of study. 
The comparison among the results illustrates stronger 
antifungal effects, especially on planktonic cells, biofilm 
mass and down-regulated ALS3 expression by G.OLNPs 
as a potential replacement therapy represents a new era of 
phytopharmaceuticals. Using combinations of relatively 
G.OLNPs with relatively expensive antifungals can lower 
the cost of therapy significantly. Hopefully, in the future, 
EOs can progress from being one of the traditional cura-
tive agents to become a widely used therapy in the mod-
ern medical domain.
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